跳至主要内容
临床试验/NCT04976959
NCT04976959进行中(未招募)1 期

High Fiber in Parkinson's Disease

Rutgers, The State University of New Jersey1 个研究点 分布在 1 个国家目标入组 60 人开始时间: 2021年7月8日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
入组人数
60
试验地点
1
主要终点
changes in microbiome composition

研究概览

简要总结

The purpose of the research is to determine the effects of a high-fiber nutritional supplement (HFS) on the bacteria, viruses, and fungi that live in different regions of the body in those with Parkinson's disease (PD). We will compare the bacteria, viruses, and fungi of those with PD to those without PD (healthy controls). We will also examine the effects of transplanting stool from humans into laboratory mice with or without Parkinson-like pathology to understand how the microbiome influences the brains of animals. We can use this information to get a better understanding of how changing the microbiome might help humans.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Single Group
主要目的
Other
盲法
None

入排标准

年龄范围
50 Years 至 75 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Parkinson's disease patients who are untreated

排除标准

  • Occupation expected to change the microbiome (e.g. sanitation worker)
  • Treatment with medications that may induce parkinsonism (e.g. metoclopramide, typical or atypical antipsychotic agents)
  • Treatment within 12 weeks with oral or intravenous antibiotics
  • Known diagnosis of inflammatory bowel disease
  • Symptomatic organic gastrointestinal (GI) disease (other than hemorrhoids and hiatal hernia) or abdominal surgeries for symptomatic gastrointestinal disease such as bowel resection, diverticular surgery, colostomy; subjects with a history of an appendectomy or gallbladder removal for non-cancerous disease more than 5 years prior to presentation are allowed.
  • Symptomatic functional GI disease that significantly impairs intestinal motility such as scleroderma or use of GI motility drugs
  • Acute illness requiring immediate hospitalization
  • Pre-existent conditions as below:
  • Liver disease (cirrhosis or persistently abnormal AST or ALT that are 2X> normal);
  • Kidney disease (creatinine>2.0 mg/dL);
  • Uncontrolled psychiatric illness;
  • Clinically important lung disease or heart failure;
  • HIV disease;
  • Alcoholism, unreliable drinking history; or consumption of alcohol more than 3 times a week or binge drinking or drinking more than or equal to 3 drinks per occasion;
  • Transplant recipients;
  • Diabetes;
  • BMI > 30
  • Clinically significant dehydration or clinically detectable ascites or peripheral edema or cardiac failure
  • Presence of short bowel syndrome or severe malnutrition with ideal body weight < or = 90%
  • Use of immunosuppressive medications in 3 months prior to enrollment
  • Anti-inflammatory medication use within 3 weeks of enrollment.
  • Chronic use of diuretics

研究组 & 干预措施

Parkinson's patients

Experimental

Parkinson's patients who will receive a high fiber supplement

干预措施: High Fiber supplement (Drug)

结局指标

主要结局

changes in microbiome composition

时间窗: 4 weeks

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Gian Dev Pal, MD, MS

Assistant Professor

Rutgers, The State University of New Jersey

研究点 (1)

Loading locations...

相似试验